Breaking News, Collaborations & Alliances

Isis Earns GSK Milestone

Advances ISIS-TTRRx

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Isis Pharmaceuticals, Inc. has earned a $1 million milestone payment from GlaxoSmithKline for the advancement of the Phase II/III study of ISIS-TTRRx in familial amyloid polyneuropathy (FAP), a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.   To date, Isis has earned $27 million in upfront and milestone payments. Should GSK exercise its option to license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulato...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters